Zobrazeno 1 - 10
of 61
pro vyhledávání: '"C. von Frenckell"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F. Vandergheynst, C Regniers, Daniel Engelbert Blockmans, C von Frenckell, J-B Nicolas, P Chasseur
Publikováno v:
Acta Clinica Belgica. 75:163-169
Introduction: The RAVE trial has revolutionized induction treatment of anti-neutrophil cytoplasmic antibodies (ANCA)-Associated Vasculitis (AAV)by demonstrating the non-inferiority of rituximab (RT...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a18f1670bc4046a5c478edded070e01
https://doi.org/10.1080/17843286.2019.1578041
https://doi.org/10.1080/17843286.2019.1578041
Autor:
J. Guiot, M. Henket, A.N. Frix, M. Delvaux, A. Denis, L. Giltay, M. Thys, F. Gester, M. Moutschen, J.L. Corhay, R. Louis, A. Ancion, A. Bouquegneau, C. Bovy, G. Darcis, J.O. Defraigne, B. Duysinx, A. Ghuysen, A. Gilbert, V. Heinen, B. Lambermont, O. Malaise, M. Martin, B. Misset, D. Nguyen Dang, J. Piazza, J. Szecel, F. Vaillant, H. Van Cauwenberge, C. Von Frenckell, L. Vroonen
Publikováno v:
Respiratory Investigation
Introduction Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients. Methods We retrospectively analyzed a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c59a00f3dc7b872b9fb22d7cc09d4cc
http://europepmc.org/articles/PMC7501770
http://europepmc.org/articles/PMC7501770
Autor:
M G, Malaise, N, Chapelier, T, Dewael, L, Leonori, M, Leroy, E, Mailleux, B, André, S, Halleux, M J, Kaiser, O, Malaise, C, Ribbens, C, Rinkin, C, von Frenckell, A, Volders
Publikováno v:
Revue medicale de Liege. 75(5-6)
The development of new drugs is a significant activity in a university hospital that favors access to therapeutic novelties to patients. Rheumatology, whose drug armamentarium was poor in the 1980s, has benefited from the huge progresses of immunolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a27d4fc1e84890cd626350e8a3012c1
https://pubmed.ncbi.nlm.nih.gov/32496682
https://pubmed.ncbi.nlm.nih.gov/32496682
Autor:
B. Duysink, F. Chauveheid, G. Colin, C. Von Frenckell, Y. Piette, E. Deflandre, Michel Malaise, Olivier Malaise
Publikováno v:
Revue du Rhumatisme. 87:A235-A236
Introduction La dermatomyosite (DM) est une maladie auto-immune rare caracterisee par une faiblesse musculaire et une eruption cutanee. Son association avec le cancer est bien connue mais le terme « paraneoplasique » reste debattu. Nous rapportons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfa334f7b453223b5775ad323fe298a0
https://doi.org/10.1016/j.rhum.2020.10.420
https://doi.org/10.1016/j.rhum.2020.10.420
Publikováno v:
Revue medicale de Liege. 74(1)
Interstitial lung diseases (ILD) are a part of a vast and heterogeneous clinicopathological entity. The work-up have to rule out a granulomatosis or a secondary cause, before making the diagnosis of an idiopathic ILD. The etiological diagnosis is bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::71f633ff55126f9a92796252539bb148
https://pubmed.ncbi.nlm.nih.gov/30680974
https://pubmed.ncbi.nlm.nih.gov/30680974
Publikováno v:
Revue medicale de Liege. 73(7-8)
Antisynthetase syndrome is a clinical entity characterized by specific anti-aminoacyl-tRNA-synthetase antibodies usually associated with inflammatory myopathy and interstitial lung disease. The classic presentation of the pathology is the pulmonary i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53c36fabb68359adf730a8d6372f6698
https://pubmed.ncbi.nlm.nih.gov/30113776
https://pubmed.ncbi.nlm.nih.gov/30113776
Publikováno v:
Saturday, 16 JUNE 2018.
Background The RAVE trial has revolutionised the induction treatment of ANCA-Associated Vasculitis (AAV, including GPA, granulomatosis with polyangiitis and MPA, microscopic polyangiitis), by demonstrating non-inferiority of rituximab compared with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb5ec9a40b733ec1acd9192863b3df6b
https://doi.org/10.1136/annrheumdis-2018-eular.1881
https://doi.org/10.1136/annrheumdis-2018-eular.1881
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
C, von Frenckell, P, Delanaye
Publikováno v:
Revue medicale de Liege. 70(2)
Three recently published randomized studies have demonstrated the efficacy of rituximab in the induction and maintenance therapy of ANCA vasculitis. This is a major advance since these types of vasculitis entail a high morbity and mortality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2bb842e30a57fa27631cb5ff2d25c39
https://pubmed.ncbi.nlm.nih.gov/26011994
https://pubmed.ncbi.nlm.nih.gov/26011994